An interventional study of Endoscopic SASI in Metabolic Syndrome, Severe Obesity and Reflux, Gastroesophageal, sponsored by Singapore Health Services. Recruiting at 3 sites in Singapore. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-02-14.
Sponsored by Singapore Health Services · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Metabolic Syndrome with a site in Singapore — 7 open to participants now, 9 under way, none of them phase 3. Metabolic Syndrome · Singapore.
Among the 15 studies in Metabolic Syndrome with a site in Singapore, this one is the only one that started in 2025, is one of 7 with no phase, and was the 11th registered.
2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.
Browse Metabolic Syndrome studies →7 of the 15 studies in Metabolic Syndrome with a site in Singapore are open now. Recruiting first, the newest first:
National University Health System, Singapore · Sites in Singapore
Ages 21–70
National University Health System, Singapore · Sites in Singapore
Ages 21–65
National Heart Centre Singapore · Sites in Singapore
Ages 21–99 · Healthy volunteers
National University Hospital, Singapore · Sites in Singapore
Ages 40–70
Sengkang General Hospital · Sites in Singapore
Ages 21–99 · Healthy volunteers
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.
This study: 21 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 60 across 1,574 interventional studies indexed under Metabolic Syndrome.
Median enrollment 135 across the 8 interventional studies, 97 across the 7 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 15 has an industry lead sponsor. The 8 most frequent:
Singapore Health Services is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Singapore Health Services has 1 study filed under Metabolic Syndrome — fewer than ten, so there is no comparison to draw.
3 of the studies in Metabolic Syndrome with a site in Singapore that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06363253Sengkang General HospitalPilot Study of the Human Metagenome in Metabolic Diseases | 2026-12-31 |
| NCT07410325National University Health System, SingaporeEffectiveness and Implementation of a Community-based Health Coach-led Artificial Intelligence (AI)-Powered Digital Self-Regulation Program for Individuals With Metabolic Syndrome (MetS) | 2027-01 |
| NCT07710274National University Health System, SingaporeEffectiveness of the Personalized Responses & Integrated Systems for Metabolism (PRISM) on Improving Insulin Resistance Among Adults With Metabolic Syndrome: A Pilot Study (PRISM-I) | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies in Metabolic Syndrome with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to determine the feasibility and effectiveness of endoscopic anastomosis of sleeve gastrectomy to ileum with a lumen apposing metal stent (LAMS) after a failed sleeve gastrectomy.
The current standard of care for patients who experience insufficient weight loss, weight re-gain or Type II diabetes relapse after a sleeve gastrectomy is a revisional laparoscopic sleeve gastrectomy.
However, such revisional procedure is commonly associated with high mortality and morbidity due to protein malnutrition. A noval bariatric procedure, single anastomosis sleeve ileal (SASI) bypass has emerged recently.
In this study, we are utilizing an incisionless novel endoscopic technique to efficiently replicate the anatomical features and physiological effects of SASI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject must meet all the inclusion criteria to participate in this study and list each criterion.
Individuals below age 21 would not be recruited as this is a study in the adult population. Individuals above age 65 are excluded to minimize the procedure risk.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Endoscopic SASI
Procedure: Endoscopic SASI
Endoscopic conversion to sleeve gastrectomy to SASI
Total amount of weight loss
Amount of weight loss after endoscopic conversion to SASI will be measured in kg and will be reported in percentage (%).
Time frame: 6 months
HbA1c
HbA1c levels will be measured and reported in percentage (%)
Time frame: 6 months
GERD symptoms
Quality of Life in Reflux And Dyspepsia (QoLRAD) is a questionnaire used to assess how gastroesophageal reflux disease (GERD) and dyspepsia (indigestion) affects a person's quality of life. The total score will be calculated from the questionnaire and a reduction in QoLRAD score over time will demonstrate improvement.
Time frame: 6 months
Feasibility & Safety
Technical success rate \& procedure related complications. Number of adverse events will be recorded at all times to determine the feasibility and safety of the study procedure.
Time frame: 30 days
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Aug 2026, 18 months after the start.
Of 627 non-industry interventional studies with no phase under Metabolic Syndrome, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 18 months is close to that.
Counting every sponsor, half of 677 studies reached it within 20 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Singapore Health Services